MLICM
ACRV icon

Metropolitan Life Insurance Company (MetLife)’s Acrivon Therapeutics ACRV Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-523
Closed -$6.64K – 2460
2023
Q1 		$6.64K Buy
+523
New +$8.78K ﹤0.01% 2257

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s ACRV Position: Q2 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Acrivon Therapeutics (ACRV) in Q2 2023, closing a stake of 523 shares — an estimated $6.64K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in ACRV in Q1 2023 and held it in 1 quarter. The position peaked at $6.64K in Q1 2023. 40 funds tracked by Wall St. Rank hold ACRV as of Q2 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Acrivon Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 523 Acrivon Therapeutics shares in Q2 2023, an estimated $6.64K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Acrivon Therapeutics in Q1 2023 and held it in 1 quarter.
  • Metropolitan Life Insurance Company (MetLife)'s Acrivon Therapeutics position peaked at $6.64K in Q1 2023.
  • 40 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2023, filed 10 Aug 2023.